<DOC>
	<DOCNO>NCT02889562</DOCNO>
	<brief_summary>In open-label , prospective , randomize pilot study , patient develop atrial fibrillation isolate coronary artery bypass graft surgery identify . Patients persistent atrial fibrillation ( &gt; 12 hour ) recurrent sustain atrial fibrillation ( &gt; 2 episode atrial fibrillation lasting longer 30 minute ) candidate inclusion . Upon meet study inclusion exclusion criterion , inform consent , patient randomize either standard care ( warfarin per protocol ) apixaban arm trial . Routine postoperative care CABG occur group . Upon discharge , anticoagulation group manage anticoagulation clinic . Patients follow 30 day surgery .</brief_summary>
	<brief_title>Apixaban Versus Warfarin Management Post-operative Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Signed Written Informed Consent Patients diagnose newonset persistent recurrent atrial fibrillation isolate CABG surgery . Persistent atrial fibrillation define episode &gt; 12 hour . Recurrent atrial fibrillation define two episode atrial fibrillation lasting longer 30 minute . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug . Patients undergo isolated CABG must test documented prior procedure , verify prior randomization . Women must breastfeed . WOCBP must agree follow instruction method ( ) contraception duration treatment study drug ( ) : 30 day treatment plus 5 halflives study drug Apixaban ( 3 day ) warfarin ( 8 day ) plus 30 day ( duration ovulatory cycle ) total 38 day posttreatment completion . Males sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment study drug ( ) : 30 day treatment plus 5 halflives study drug Apixaban ( 3 day ) warfarin ( 8 day ) plus 90 day ( duration sperm turnover ) total 98 day posttreatment completion . Atrial fibrillation due reversible cause recent surgery Patients diagnose persistent paroxysmal atrial fibrillation chronically undergoing surgery Patients mechanical heart valves Patients currently experience active bleeding preclude initialization anticoagulation therapy opinion manage physician , increase bleeding risk ( determined attend surgeon ) believe contraindication anticoagulation time randomization Planned major surgery require stoppage anticoagulation therapy trial period Stroke within previous 7 day Moderate severe mitral stenosis Conditions atrial fibrillation require anticoagulation ( prosthetic mechanical heart valve ) Patients take warfarin , apixaban , rivaroxaban , dabigatran , edoxaban , clopidogrel , ticagrelor , enoxaparin home indication 15 day prior surgery Patients require use clopidogrel ticagrelor study period Severe renal insufficiency ( serum creatinine level &gt; 2.5 mg/dL CrCL &lt; 25 ml/min ) consecutive measurement Allergies warfarin apixaban , component warfarin apixaban</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>apixaban</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>CABG</keyword>
	<keyword>thrombosis</keyword>
	<keyword>fibrillation</keyword>
</DOC>